arrow_back Back to App

Tax Credits for US Generic Drug and Biosimilar Production

This new law introduces tax credits for companies manufacturing generic drugs and biosimilars in the United States. The aim is to boost domestic production of these medicines, potentially leading to greater availability and stable supplies of essential medications for citizens. Additionally, the act supports investments in manufacturing facilities within the US.
Key points
Companies producing generic drugs and biosimilars in the US can receive tax credits, encouraging local manufacturing.
Higher credits are available for final drug products and those with more US-produced components.
The act also provides investment credits for building and equipping new generic drug and biosimilar manufacturing facilities in the United States.
The goal is to enhance drug supply security and reduce reliance on foreign manufacturers, potentially impacting drug prices and patient access.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1891
Sponsor: Sen. Cotton, Tom [R-AR]
Process start date: 2025-05-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PILLS Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1891.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-05-22.

What are the main provisions?

Key points include:

  • Companies producing generic drugs and biosimilars in the US can receive tax credits, encouraging local manufacturing.
  • Higher credits are available for final drug products and those with more US-produced components.
  • The act also provides investment credits for building and equipping new generic drug and biosimilar manufacturing facilities in the United States.
  • The goal is to enhance drug supply security and reduce reliance on foreign manufacturers, potentially impacting drug prices and patient access.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cotton, Tom [R-AR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Taxes Health Economy